Peripartum cardiomyopathy

doi:10.3877/cma.j.issn.2095-3259.2022.02.002

Abstract

Abstract:

Peripartum cardiomyopathy (PPCM) is a left ventricular systolic dysfunction heart disease with heart failure as the main manifestation. It mainly occurs in from 28 weeks of pregnancy to 6 months after delivering, and black women are the main affected group. Its pathogenesis is still not completely clear, but the vascular hormone pathway may be the main pathogenesis. Currently, the treatment principle is the BOARD therapies, including bromocriptine and anti-heart failure as the main treatment.

Key words: Cardiomyopathy, dilated, Heart failure, Therapy

Zhijian Wang, Zhenqin Huang. Peripartum cardiomyopathy[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2022, 11(02): 72-76.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2022.02.002

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I02/72

References 37

[1]	Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy [J]. Eur Heart J，2018，39(34)：3165-3241.
[2]	Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy [J]. Eur J Heart Fail，2019，21(7)：827-843.
[3]	中华医学会心血管病学分会，中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南 [J]. 临床心血管病杂志，2018，34(5)：421-434.
[4]	Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review [J]. JAMA, 2000，283(9): 1183-1188.
[5]	Isogai T, Kamiya CA. Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality [J]. Int Heart J, 2019, 60(3)：503-511.
[6]	Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital [J]. Ethn Dis，2007，17(2)：228-233.
[7]	Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution [J]. Mayo Clin Proc, 2005, 80(12)：1602-1606.
[8]	Kuklina EV, Callaghan WM. Cardiomyopathy and other myocardial disorders among hospitalizations for pregnancy in the United States: 2004-2006 [J]. Obstet Gynecol，2010，115(1)：93-100.
[9]	Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study[J]. J Am Heart Assoc，2014，3(3)：1-13.
[10]	Gentry MB, Dias JK, Luis A, et al. African-American women have a higher risk for developing peripartum cardiomyopathy [J]. J Am Coll Cardiol, 2010，55(7): 654-659.
[11]	岳晓辉，刘楠，薛晓艳. 我国围产期心肌病流行病学特点及转归荟萃分析 [J]. 中国妇产科临床杂志，2011，12(5)：359-363.
[12]	Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis [J]. Trends Cardiovasc Med，2015，25(6)：499-504.
[13]	Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy [J]. Lancet, 2006, 368 (9536): 687-693.
[14]	Cunningham FG, Byrne JJ, Nelson DB. Peripartum Cardiomyopathy [J]. Obstet Gynecol, 2019，133(1)：167-179.
[15]	Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies [J]. N Engl J Med，2016，374(3)：233-241.
[16]	Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy [J]. Cell, 2007，128(3): 589-600.
[17]	Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study [J]. Eur Heart J，2017，38(35)：2671-2679.
[18]	Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy [J]. J Clin Invest, 2013, 123(5): 2143-2154.
[19]	Stapel B, Kohlhaas M, Ricke-Hoch M, et al. Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy [J]. Eur Heart J, 2017，38(5)：349-361.
[20]	车千秋，王琼英，梁宇博，等. 围产期心肌病的病因学研究进展[J]. 中华心力衰竭和心肌病杂志，2019，3(1)：41-44.
[21]	Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy [J]. Nature, 2012, 485(7398)：333-338.
[22]	Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study [J]. JACC Heart Fail，2016，4(5)：380-388.
[23]	Goland S, Weinstein JM, Zalik A, et al. Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients [J]. Circ Heart Fail, 2016，9(11)：1-7.
[24]	Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management[J]. J Am Coll Cardiol, 2011, 58(7): 659-670.
[25]	赵敏琦. 围产期心肌病的诊断与治疗新进展 [J]. 中国实用妇科与产科杂志，2013，29(5)：386-389.
[26]	Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy [J]. J Am Coll Cardiol，2014，64(15)：1629-1636.
[27]	Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association [J]. Circulation, 2016，134(23)：e535-e578.
[28]	Ezekowitz JA, O′Meara E, Mcdonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure[J]. Can J Cardiol, 2017，33(11)：1342-1433.
[29]	Hoevelmann J, Viljoen CA, Manning K, et al. The prognostic significance of the 12-lead ECG in peripartum cardiomyopathy[J]. Int J Cardiol，2019，276：177-184.
[30]	Arany Z, Elkayam U. Peripartum Cardiomyopathy [J]. Circulation, 2016，133(14)：1397-1409.
[31]	Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD [J]. Eur Heart J，2017，38(35)：2680-2682.
[32]	Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study [J]. Circulation，2010，121(13)：1465-1473.
[33]	Haghikia A, Podewski E, Berliner D, et al. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy [J]. Clin Res Cardiol, 2015，104(11)：911-917.
[34]	刘燕燕，冯玲. 围产期心肌病诊治[J]. 中国实用妇科与产科杂志，2019, 35(11)：1224-1228.
[35]	Beadle RM, Williams LK, Kuehl M, et al. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy [J]. JACC Heart Fail, 2015, 3(3)：202-211.
[36]	Honigberg MC, Givertz MM. Peripartum cardiomyopathy [J]. BMJ, 2019, 364: 1-14.
[37]	Elkayam U, Goland S, Pieper PG, et al. High-Risk Cardiac Disease in Pregnancy: Part Ⅱ [J]. J Am Coll Cardiol, 2016，68(5)：502-516.

Please choose a citation manager

Content to export